{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:12:52Z","timestamp":1788883972076,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.tiv.2021.105137","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T04:51:32Z","timestamp":1615092692000},"page":"105137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"74","author":[{"given":"Adinarayana","family":"Nandikolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Singireddi","family":"Srinivasarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh Mahadu","family":"Khetmalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banoth Karan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankaranarayanan","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Shetye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Franzblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kondapalli Venkata Gowri Chandra","family":"Sekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2021.105137_bb0005","doi-asserted-by":"crossref","first-page":"e52951","DOI":"10.1371\/journal.pone.0052951","article-title":"Identification of novel Imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB","volume":"7","author":"Abrahams","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tiv.2021.105137_bb0010","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1039\/C4CC08495K","article-title":"Synthesis of imidazo[1,2-a]pyridines: a decade update","volume":"51","author":"Bagdi","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.tiv.2021.105137_bb0015","doi-asserted-by":"crossref","first-page":"D464","DOI":"10.1093\/nar\/gky1004","article-title":"RCSB protein data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy","volume":"47","author":"Burley","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tiv.2021.105137_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejmech.2018.03.020","article-title":"Drug discovery in tuberculosis. New drug targets and antimycobacterial agents","volume":"150","author":"Campani\u00e7o","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0025","doi-asserted-by":"crossref","first-page":"e87483","DOI":"10.1371\/journal.pone.0087483","article-title":"Bactericidal activity of an Imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tiv.2021.105137_bb0030","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1128\/AAC.00055-06","article-title":"Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis","volume":"51","author":"Cho","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tiv.2021.105137_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-4939-2450-9_17","article-title":"Microplate Alamar blue assay (MABA) and low oxygen recovery assay (LORA) for Mycobacterium tuberculosis","volume":"1285","author":"Cho","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tiv.2021.105137_bb0040","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2174\/138955707781662645","article-title":"Recent progress in the pharmacology of imidazo [1, 2- a] pyridines","volume":"7","author":"Enguehard-gueiffier","year":"2007","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejmech.2018.03.016","article-title":"Recent advances of imidazole-containing derivatives as anti-tubercular agents","volume":"150","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0050","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/JCM.36.2.362-366.1998","article-title":"Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar blue assay","volume":"36","author":"Franzblau","year":"1998","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.tiv.2021.105137_bb0055","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0060","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1016\/j.bmcl.2008.09.096","article-title":"Clubbed [1,2,3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis","volume":"18","author":"Gill","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0065","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/jm060715y","article-title":"Pyrrolidine Carboxamides as a novel class of inhibitors of Enoyl acyl carrier protein reductase from Mycobacterium tuberculosis","volume":"49","author":"He","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0070","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1016\/j.bmcl.2013.10.016","article-title":"Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4- yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents","volume":"23","author":"Hunsur","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0075","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.bmcl.2015.08.009","article-title":"One-pot synthesis of new triazole\u2014Imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity","volume":"25","author":"Jurupula","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0080","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.bmcl.2016.03.059","article-title":"Seeking potent anti-tubercular agents: design, synthesis, anti-tubercular activity and docking study of various ((triazoles\/indole)-piperazin-1-yl\/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives","volume":"26","author":"Kalaga","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejmech.2017.05.021","article-title":"Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents","volume":"136","author":"Kang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bmcl.2018.11.036","article-title":"Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents","volume":"29","author":"Kasa","year":"2019","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cclet.2019.07.038","article-title":"N-(2-Phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides containing various amine moieties: design, synthesis and antitubercular activity","volume":"31","author":"Li","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0100","doi-asserted-by":"crossref","first-page":"128360","DOI":"10.1016\/j.molstruc.2020.128360","article-title":"Synthesis, biological evaluation, molecular docking, molecular dynamics and DFT studies of quinoline-fluoroproline amide hybrids","volume":"1217","author":"Moorthiamma","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.tiv.2021.105137_bb0105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/ml200036r","article-title":"Advent of imidazo[1,2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity","volume":"2","author":"Moraski","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/id500008t","article-title":"Putting tuberculosis (TB) to rest: transformation of the sleep aid, Ambien, and \u201canagrams\u201d generated potent Antituberculosis agents","volume":"1","author":"Moraski","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.tiv.2021.105137_bb0115","doi-asserted-by":"crossref","first-page":"38328","DOI":"10.1039\/D0RA07881F","article-title":"Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues","volume":"10","author":"Nandikolla","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.tiv.2021.105137_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060531","article-title":"A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis","volume":"8","author":"Ollinger","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tiv.2021.105137_bb0125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/cbdd.13739","article-title":"Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridinecarboxamides as potent anti-tuberculosis agents","volume":"96","author":"Onajole","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.tiv.2021.105137_bb0130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejmech.2015.10.024","article-title":"Design, synthesis and evaluation of diarylpiperazine derivatives as potent anti-tubercular agents","volume":"105","author":"Penta","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0135","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.tiv.2021.105137_bb0140","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1007\/s00044-020-02602-8","article-title":"Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities","volume":"29","author":"Pola","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.tiv.2021.105137_bb0145","series-title":"Q.U. Manual, QikProp Descriptors and Properties PISA","first-page":"2","author":"QU. Manual","year":"2015"},{"key":"10.1016\/j.tiv.2021.105137_bb0150","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1021\/jm2008826","article-title":"Novel N-linked Aminopiperidine inhibitors of bacterial topoisomerase type II: broad-Spectrum antibacterial agents with reduced hERG activity","volume":"54","author":"Reck","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0155","doi-asserted-by":"crossref","first-page":"126846","DOI":"10.1016\/j.bmcl.2019.126846","article-title":"The bioisosteric modification of pyrazinamide derivatives led to potent antitubercular agents: synthesis via click approach and molecular docking of pyrazine-1,2,3-triazoles","volume":"30","author":"Reddyrajula","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.tiv.2021.105137_bb0160","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: an open-source program for chemistry aware data visualization and analysis","volume":"55","author":"Sander","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.tiv.2021.105137_bb0165","series-title":"Maestro, Schr\u00f6dinger","author":"Schr\u00f6dinger Release 2019-1","year":"2019"},{"key":"10.1016\/j.tiv.2021.105137_bb0170","doi-asserted-by":"crossref","first-page":"103955","DOI":"10.1016\/j.bioorg.2020.103955","article-title":"Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents","volume":"100","author":"Singireddi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0175","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.ejmech.2011.03.039","article-title":"New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents","volume":"46","author":"Thomas","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tiv.2021.105137_bb0180","series-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.tiv.2021.105137_bb0185","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acsmedchemlett.6b00330","article-title":"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as new Antituberculosis agents","volume":"7","author":"Wu","year":"2016","journal-title":"ACS Med. Chem. Lett."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088723332100062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088723332100062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:08Z","timestamp":1760135828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088723332100062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"alternative-id":["S088723332100062X"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2021.105137","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel 1,2,3-triazole analogues of Imidazo-[1,2-a]-pyridine-3-carboxamide against Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2021.105137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105137"}}